According to Paratek Pharmaceuticals 's latest financial reports the company's current earnings (TTM) are -$43.71 M. In 2022 the company made an earning of -$45.39 M a decrease over its 2021 earnings that were of -$41.08 M.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$43.71 M | -3.71% |
2022 | -$45.39 M | 10.5% |
2021 | -$41.08 M | -46.16% |
2020 | -$76.31 M | -31.93% |
2019 | -$0.12 B | 11.12% |
2018 | -$0.11 B | 21.19% |
2017 | -$83.24 M | -23.22% |
2016 | -$0.11 B | 54.68% |
2015 | -$70.09 M | 309.5% |
2014 | -$17.12 M | -29.88% |
2013 | -$24.41 M | |
2011 | -$3.77 M | -59.18% |
2010 | -$9.23 M | -53.53% |
2009 | -$19.85 M | -161.93% |
2008 | $32.04 M | -187.43% |
2007 | -$36.66 M | 11.93% |
2006 | -$32.75 M | 31.69% |
2005 | -$24.87 M | 32.4% |
2004 | -$18.78 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Ultragenyx RARE | -$0.55 B | 1,141.13% | ๐บ๐ธ USA |
Spectrum Pharmaceuticals
SPPI | -$61.89 M | 41.58% | ๐บ๐ธ USA |
Agenus
AGEN | -$0.16 B | 264.96% | ๐บ๐ธ USA |